Den europeiske union - portugisisk - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agentes antineoplásicos - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. para mais informações sobre o status do receptor do fator de crescimento epidérmico humano (her2), consulte a seção 5. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. para mais informações sobre o status her2, consulte a seção 5. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Den europeiske union - portugisisk - EMA (European Medicines Agency)

bayer pharma ag - regorafenib - neoplasias colorretais - antineoplastic agents, protein kinase inhibitors - stivarga é indicado como monoterapia para o tratamento de pacientes adultos com:câncer colorretal metastático (crc), que foram previamente tratados com, ou que não são considerados candidatos para, terapias disponíveis - estes incluem fluoropyrimidine base de quimioterapia, um anti-vegf terapia e um anti-egfr terapia;ou metastático, irressecável tumores estromais gastrointestinais (gist), que progrediu ou são intolerantes antes do tratamento com imatinib e sutent;carcinoma hepatocelular (chc), que foram previamente tratados com sorafenib.

Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

serb s.a. - gentamicina - implante - 32.5 mg - gentamicina, sulfato 54.17 mg - gentamicin - n/a - duração do tratamento: curta ou média duração

Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

serb s.a. - gentamicina - implante - 130 mg - gentamicina, sulfato 216.67 mg - gentamicin - n/a - duração do tratamento: curta ou média duração

Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

serb s.a. - gentamicina - implante - 32.5 mg - gentamicina, sulfato 54.17 mg - gentamicin - n/a - duração do tratamento: curta ou média duração

Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

serb s.a. - gentamicina - implante - 32.5 mg - gentamicina, sulfato 54.17 mg - gentamicin - n/a - duração do tratamento: curta ou média duração

Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

serb s.a. - gentamicina - implante - 130 mg - gentamicina, sulfato 216.67 mg - gentamicin - n/a - duração do tratamento: curta ou média duração

Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

serb s.a. - gentamicina - implante - 130 mg - gentamicina, sulfato 216.67 mg - gentamicin - n/a - duração do tratamento: curta ou média duração

Brasil - portugisisk - ANVISA (Agência Nacional de Vigilância Sanitária)

libbs farmacÊutica ltda - folinato de cÁlcio - antimetabolicos antagonistas do acido folico

Brasil - portugisisk - ANVISA (Agência Nacional de Vigilância Sanitária)

eurofarma laboratÓrios s.a. - folinato de cÁlcio - antimetabolicos antagonistas do acido folico